Bain Capital Life Sciences Investors, LLC Long-Term Concentrated

Name: Bain Capital Life Sciences Investors, LLC Q2 2020 13F Filing | 13F Explorer
Creator: Bain Capital Life Sciences Investors, LLC
Published: 2020-08-14

Location: Boston, MA

CIK: 0001703031 · Show all filings

Period: Q2 2020 (← Previous) (Next →)

Filing Date: Aug 14, 2020

Total Value: $955M (100.0% shares, 0.0% debt)

Holdings (15)

— SPRINGWORKS THERAPEUTICS INC 32.0%

Value $306M Shares 7,281,307 Est. Cost $21.68 Unrealized —

ARQT ARCUTIS BIOTHERAPEUTICS, INC. 12.6%

Value $120M Shares 3,979,292 Est. Cost $26.87 Unrealized +7.6%

— DICERNA PHARMACEUTICALS INC 10.9%

Value $104M Shares 4,080,237 Est. Cost $9.03 Unrealized —

— DYNAVAX TECHNOLOGIES CORP. 10.1%

Value $96.65M Shares 10,895,773 Est. Cost $4.63 Unrealized —

— MERSANA THERAPEUTICS, INC. 8.4%

Value $80.63M Shares 3,445,667 Est. Cost $23.40 Unrealized —

REPL REPLIMUNE GROUP INC 5.6%

Value $53.74M Shares 2,162,598 Est. Cost $17.53 Unrealized +0.9%

— CONSTELLATION PHARMACEUTICALS INC. 4.4%

Value $42.07M Shares 1,400,000 Est. Cost $47.11 Unrealized —

— AEGLEA BIOTHERAPEUTICS, INC. 2.6%

Value $24.98M Shares 2,700,000 Est. Cost $9.25 Unrealized —

— APTINYX INC 2.4%

Value $23.18M Shares 5,558,425 Est. Cost $10.97 Unrealized —

SVRA SAVARA INC 2.4%

Value $22.98M Shares 5,128,593 Est. Cost $1.20 Unrealized +102.1%

— SAGE THERAPEUTICS, INC. 2.2%

Value $20.75M Shares 499,100 Est. Cost $41.58 Unrealized —

CRNX CRINETICS PHARMACEUTICALS, INC. 2.0%

Value $18.77M Shares 1,071,428 Est. Cost $17.05 Unrealized 0.0%

— X4 PHARMACEUTICALS INC 1.6%

Value $15.36M Shares 1,648,485 Est. Cost $10.70 Unrealized —

— MARINUS PHARMACEUTICALS INC 1.5%

Value $14.54M Shares 5,724,235 Est. Cost $6.30 Unrealized —

— SOLID BIOSCIENCES INC 1.2%

Value $11.34M Shares 3,871,164 Est. Cost $8.88 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	SPRINGWORKS THERAPEUTICS INC	7,281,307	$306M	32.0%	$21.68	—	COM	85205L107
ARQT	ARCUTIS BIOTHERAPEUTICS, INC.	3,979,292	$120M	12.6%	$26.87	+7.6%	COM	03969K108
—	DICERNA PHARMACEUTICALS INC	4,080,237	$104M	10.9%	$9.03	—	COM	253031108
—	DYNAVAX TECHNOLOGIES CORP.	10,895,773	$96.65M	10.1%	$4.63	—	COM	268158201
—	MERSANA THERAPEUTICS, INC.	3,445,667	$80.63M	8.4%	$23.40	—	COM	59045L106
REPL	REPLIMUNE GROUP INC	2,162,598	$53.74M	5.6%	$17.53	+0.9%	COM	76029N106
—	CONSTELLATION PHARMACEUTICALS INC.	1,400,000	$42.07M	4.4%	$47.11	—	COM	210373106
—	AEGLEA BIOTHERAPEUTICS, INC.	2,700,000	$24.98M	2.6%	$9.25	—	COM	00773J103
—	APTINYX INC	5,558,425	$23.18M	2.4%	$10.97	—	COM	03836N103
SVRA	SAVARA INC	5,128,593	$22.98M	2.4%	$1.20	+102.1%	COM	805111101
—	SAGE THERAPEUTICS, INC.	499,100	$20.75M	2.2%	$41.58	—	COM	78667J108
CRNX	CRINETICS PHARMACEUTICALS, INC.	1,071,428	$18.77M	2.0%	$17.05	0.0%	COM	22663K107
—	X4 PHARMACEUTICALS INC	1,648,485	$15.36M	1.6%	$10.70	—	COM	98420X103
—	MARINUS PHARMACEUTICALS INC	5,724,235	$14.54M	1.5%	$6.30	—	COM	56854Q101
—	SOLID BIOSCIENCES INC	3,871,164	$11.34M	1.2%	$8.88	—	COM	83422E105